Combination therapy for advanced KRAS-mutated bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bile duct cancer (intrahepatic cholangiocarcinoma) with a KRAS mutation.
- You are 18 years or older.
- Your cancer has gotten worse after 1 or 2 rounds of chemotherapy.
- You have at least one tumor that can be measured on a scan.
- You are in fairly good health (able to do everyday activities) and have normal organ function.
- You have not had a MEK inhibitor or autophagy inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment combination for advanced bile duct or gallbladder cancer that has not been treated before. It aims to slow cancer growth and may be a good option if you have not had prior therapy for your cancer.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
This trial is testing treatments that are customized to the specific genetic changes in your bile duct or gallbladder cancer. The goal is to find a drug that targets your tumor's unique mutation, which may help control the cancer better than a one-size-fits-all approach.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.